SEC receives amended S-1/A filing for 21Shares Injective ETF as altcoin ETF race heats up

The SEC has received an amended registration statement for the 21Shares Injective ETF, moving the proposed fund one step closer to potentially becoming a publicly traded product. The amended S-1/A updates the original filing from October 2025, and would give traditional investors regulated access to INJ, the native token of the Injective Network. If approved, the ETF would list on Nasdaq under the ticker TINJ. The fund’s strategy centers on passively tracking INJ token performance via the FTSE Injective Index, with an added twist: discretionary staking of a portion of holdings to boost returns. What the filing reveals The 21Shares Injective ETF is structured as a Delaware statutory trust, sponsored by 21Shares US LLC. The original S-1 landed on the SEC’s desk on October 20, 2025, and this latest amendment keeps the registration active and updated as the review process continues. The preliminary prospectus makes clear that shares haven’t traded publicly yet, and no financial statements are included at this stage. The fund plans to stake a portion of its INJ holdings at its discretion, a strategy designed to optimize performance while staying within regulatory guardrails. Staking rew...